Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, Medical Correspondent at OncLive, shared on LinkedIn about a recent article he and his colleagues co-authored, published in Encyclopedia, adding:
“For decades, a cure for sickle cell disease (SCD) depended on finding the right donor for an allogeneic stem cell transplant – a life-saving option that remained out of reach for many patients and carried the lifelong risk of graft-versus-host disease (GVHD).
Today, that paradigm is changing.
The emergence of autologous gene therapies, including Lyfgenia and Casgevy, has ushered in a new era of precision medicine, offering curative potential without the need for a donor or the risk of GVHD.
At the same time, advances in transplantation continue to expand access and improve outcomes, making treatment decisions more complex – and more exciting – than ever before.
In our new review, we explore:
- How stem cell transplantation has evolved over the past several decades
- The science and clinical data behind gene-editing and gene-addition therapies
- The strengths and limitations of each curative strategy
- The remaining barriers to affordability, accessibility, and global implementation
As curative therapies move from promise to clinical reality, understanding where the field stands – and where it’s headed – is essential for clinicians, researchers, and patients alike.”
Title: The New Era of Curative Therapies for Sickle Cell Disease: A Comprehensive Review of Allogeneic Transplantation and Autologous Gene Therapy
Authors: Ahmed Hashim Azeez, Sreesha Phani Durga Rithika Kodamanchili, Vraj JigarKumar Rangrej, Harshitha Vallabhaneni, Yan Leyfman, Adhith Theyver, Taha Kassim Dohadwala, Chandler Park
Stay updated with Hemostasis Today.
-
Sep 1, 2026, 08:24Cristina Chang: The Importance of The New ET Treatments
-
Sep 1, 2026, 07:22Abdul Mannan: ASH 2026 Guidelines – New Treatment Approach for Adult ITP
-
Sep 1, 2026, 07:20Alejandro González Veliz: Silent Atherosclerosis Starts Earlier Than We Think
-
Sep 1, 2026, 07:18Alan Nurden: A New Mechanism Behind Immune Thrombocytopenia
-
Sep 1, 2026, 07:18Susan Shea: New NHLBI Fellowship Supports Thrombinflammation Research
-
Sep 1, 2026, 07:12Sriraman Punniakoti: Pediatric ALL Therapy and Cerebrovascular Thrombosis
-
Sep 1, 2026, 07:04Piotr Czempik: ROTEM in Sepsis-Related Coagulopathy
-
Sep 1, 2026, 07:02Amin Omar Khlifat: Reading the Laboratory Clues to Differentiate Types of Anemia
-
Sep 1, 2026, 06:14Paolo Albino Ferrari: AnemiaScore for Cancer-Related Anemia Management